These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34557727)

  • 1. Key Milestones in HCV Discovery and Therapeutics.
    Cheng X; Ghany MG
    Innovation (Camb); 2020 Nov; 1(3):100067. PubMed ID: 34557727
    [No Abstract]   [Full Text] [Related]  

  • 2. Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada.
    O'Neil CR; Buss E; Plitt S; Osman M; Coffin CS; Charlton CL; Shafran S
    Can J Public Health; 2019 Dec; 110(6):714-721. PubMed ID: 31222618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening.
    Norton BL; Southern WN; Steinman M; Smith BD; Deluca J; Rosner Z; Litwin AH
    Clin Gastroenterol Hepatol; 2016 Sep; 14(9):1356-60. PubMed ID: 27108792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C: milestones from discovery to clinical cure.
    Hu W; Zhang C; Shi JJ; Zhang JY; Wang FS
    Mil Med Res; 2020 Dec; 7(1):59. PubMed ID: 33261650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.
    Shahid I; ALMalki WH; Hafeez MH; Hassan S
    Crit Rev Microbiol; 2016 Aug; 42(4):535-47. PubMed ID: 25373616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
    Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
    Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor.
    Liu N; Zhu S; Zhang X; Yin X; Dong G; Yao J; Miao Z; Zhang W; Zhang X; Sheng C
    Chem Commun (Camb); 2016 Feb; 52(16):3340-3. PubMed ID: 26822629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A brief history of hepatitis milestones.
    Trepo C
    Liver Int; 2014 Feb; 34 Suppl 1():29-37. PubMed ID: 24373076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring protein communities and their responses to therapeutics.
    Budayeva HG; Kirkpatrick DS
    Nat Rev Drug Discov; 2020 Jun; 19(6):414-426. PubMed ID: 32139903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
    Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
    J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between models of care and key rehabilitation milestones following unilateral transtibial amputation: a national cross-sectional study.
    Hebenton J; Scott H; Seenan C; Davie-Smith F
    Physiotherapy; 2019 Dec; 105(4):476-482. PubMed ID: 31732097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
    Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
    Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus: molecular biology & current therapeutic options.
    Sharma SD
    Indian J Med Res; 2010 Jan; 131():17-34. PubMed ID: 20167971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV versus HIV drug discovery: Déjà vu all over again?
    Watkins WJ; Desai MC
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2281-7. PubMed ID: 23489621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention in buprenorphine treatment is associated with improved HCV care outcomes.
    Norton BL; Beitin A; Glenn M; DeLuca J; Litwin AH; Cunningham CO
    J Subst Abuse Treat; 2017 Apr; 75():38-42. PubMed ID: 28237052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C therapeutics: current status and emerging strategies.
    Tan SL; Pause A; Shi Y; Sonenberg N
    Nat Rev Drug Discov; 2002 Nov; 1(11):867-81. PubMed ID: 12415247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Drug Discovery of HCV Helicase Inhibitor: Improved Docking Accuracy with Multiple Seeding in AutoDock Vina and In Situ Minimization.
    Lim SK; Othman R; Yusof R; Heh CH
    Curr Comput Aided Drug Des; 2017; 13(2):160-169. PubMed ID: 27903217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The milestones for psychosomatic medicine subspecialty training.
    Boland RJ; Becker M; Levenson JL; Servis M; Crone CC; Edgar L; Thomas CR
    Psychosomatics; 2015; 56(2):153-67. PubMed ID: 25660433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-genotypic Hepatitis C Virus Inhibition by Natural Products Derived from the Wild Egyptian Artichoke.
    Elsebai MF; Koutsoudakis G; Saludes V; Pérez-Vilaró G; Turpeinen A; Mattila S; Pirttilä AM; Fontaine-Vive F; Mehiri M; Meyerhans A; Diez J
    J Virol; 2016 Feb; 90(4):1918-30. PubMed ID: 26656684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.